These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 23773018

  • 41. Transfusion related acute lung injury (TRALI) caused by red blood cell transfusion involving residual plasma anti-HLA antibodies: a report on two cases and general considerations.
    Odent-Malaure H, Quainon F, Ruyer-Dumontier P, Ducroz S, Verdier P, Voitellier E, Raynal MF, Fromont P, Muller JY, Rebibo D, Absi L, Garraud O.
    Clin Dev Immunol; 2005 Dec; 12(4):243-8. PubMed ID: 16584109
    [Abstract] [Full Text] [Related]

  • 42. Transfusion-related acute lung injury: current concepts for the clinician.
    Triulzi DJ.
    Anesth Analg; 2009 Mar; 108(3):770-6. PubMed ID: 19224781
    [Abstract] [Full Text] [Related]

  • 43. Investigations into the role of anti-HLA class II antibodies in TRALI.
    Kao GS, Wood IG, Dorfman DM, Milford EL, Benjamin RJ.
    Transfusion; 2003 Feb; 43(2):185-91. PubMed ID: 12559014
    [Abstract] [Full Text] [Related]

  • 44. A possible case of recipient anti-neutrophil and anti-human leukocyte antigen antibody-mediated fatal reverse transfusion-related acute lung injury.
    Jug R, Anani W, Callum J.
    Transfusion; 2021 Apr; 61(4):1336-1340. PubMed ID: 33666248
    [Abstract] [Full Text] [Related]

  • 45. Are we underestimating reverse TRALI?
    De Clippel D, Emonds MP, Compernolle V.
    Transfusion; 2019 Sep; 59(9):2788-2793. PubMed ID: 31241780
    [Abstract] [Full Text] [Related]

  • 46. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services.
    Lin Y, Saw CL, Hannach B, Goldman M.
    Transfusion; 2012 Mar; 52(3):567-74. PubMed ID: 21895676
    [Abstract] [Full Text] [Related]

  • 47. The effect of platelet-derived microparticles in stored apheresis platelet concentrates on polymorphonuclear leucocyte respiratory burst.
    Xie RF, Hu P, Li W, Ren YN, Yang J, Yang YM, Wang ZY, Fan HH.
    Vox Sang; 2014 Apr; 106(3):234-41. PubMed ID: 24138005
    [Abstract] [Full Text] [Related]

  • 48. The impact of policies to restrict the use of plasma containing products and apheresis platelets from female donors to mitigate transfusion related acute lung injury (TRALI) in Brazil.
    Blatyta PF, Custer B, Liu J, Mendrone-Junior A, Wright DJ, Leão SC, Lopes MI, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, NHLBI Retrovirus Epidemiology Donor Study-II (REDSII), International Component.
    Transfus Apher Sci; 2013 Feb; 48(1):15-20. PubMed ID: 22985535
    [Abstract] [Full Text] [Related]

  • 49. Donor screening as a TRALI risk reduction strategy.
    Murphy MF, Navarrete C, Massey E.
    Transfusion; 2009 Sep; 49(9):1779-82. PubMed ID: 19735501
    [No Abstract] [Full Text] [Related]

  • 50. Use of single donor platelets.
    Kirkley SA, Blumberg N.
    Blood Rev; 1994 Sep; 8(3):142-7. PubMed ID: 7819816
    [Abstract] [Full Text] [Related]

  • 51. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, Chen Y, Liu J, Chen D, Ye X, Santoso S.
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [Abstract] [Full Text] [Related]

  • 52. Accumulation of CD62P during storage of apheresis platelet concentrates and the role of CD62P in transfusion-related acute lung injury.
    Tong S, Wang H, Zhang T, Chen L, Liu B.
    Mol Med Rep; 2015 Nov; 12(5):7777-81. PubMed ID: 26397744
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Analysis of leucocyte antibodies, cytokines, lysophospholipids and cell microparticles in blood components implicated in post-transfusion reactions with dyspnoea.
    Maślanka K, Uhrynowska M, Łopacz P, Wróbel A, Smoleńska-Sym G, Guz K, Lachert E, Ostas A, Brojer E.
    Vox Sang; 2015 Jan; 108(1):27-36. PubMed ID: 25134637
    [Abstract] [Full Text] [Related]

  • 55. Transfusion-related acute lung injury (TRALI): a case report and literature review.
    Donelan KJ, Anderson KA.
    S D Med; 2011 Mar; 64(3):85-8. PubMed ID: 21473518
    [Abstract] [Full Text] [Related]

  • 56. TRALI risk reduction: donor and component management strategies.
    Eder AF, Benjamin RJ.
    J Clin Apher; 2009 Mar; 24(3):122-9. PubMed ID: 19365816
    [Abstract] [Full Text] [Related]

  • 57. Prevalence of anti-HLA antibodies in COVID-19 convalescent plasma donors: an Indian experience.
    Jaiswal RM, Tiwari AK, Singla A, Jain A, Vohra R, Kakkar M, Suravajhala P.
    Hematol Transfus Cell Ther; 2024 Mar; 46(4):455-461. PubMed ID: 39097433
    [Abstract] [Full Text] [Related]

  • 58. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention.
    Peters AL, Van Stein D, Vlaar AP.
    Br J Haematol; 2015 Sep; 170(5):597-614. PubMed ID: 25921271
    [Abstract] [Full Text] [Related]

  • 59. Human neutrophil antibodies in a blood donor population: a lookback study.
    Gottschall J, Triulzi D, Kakaiya R, Carrick D, Roback JD, Carey P, Kleinman S, NHLBI Retrovirus Epidemiology Donor Study-II.
    Vox Sang; 2013 Feb; 104(2):166-70. PubMed ID: 22998453
    [Abstract] [Full Text] [Related]

  • 60. Implementation of a strategy to prevent TRALI in a regional blood centre.
    Insunza A, Romon I, Gonzalez-Ponte ML, Hoyos A, Pastor JM, Iriondo A, Hermosa V.
    Transfus Med; 2004 Apr; 14(2):157-64. PubMed ID: 15113380
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.